Low molecular weight heparins and coronary artery disease

Current Cardiology Reports

Volumn 2, Issue 1, 2000, Pages 61-68

  Zed, Peter J ^a  

^a Clinical Services Unit Pharmaceutical Sciences Vancouver Acute Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; CORONARY DISEASE; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0033643309     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0027-0     Document Type: Article

References (44)

1. Theroux P, Fuster V: Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction. Circulation 1998, 97:1195-1206.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326 242-250.
3. Theroux P, Ouimet H, McCans J, et al. : Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319:1105-1111.
4. The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990, 336 827-830.
5. Theroux P, Waters D, Qiu S, et al. : Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88(part 1):2045-2048.
6. Cohen M, Adams PC, Parry G, et al. : Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation 1994, 89:81-88.
7. Neri Serneri GG, Modesti PA, Gensini GF, et al. : Randomized comparison of subcutaneous heparin, intravenous heparin and aspirin in unstable angina. Lancet 1995 345:1201-1204.
8. Theroux P, Waters D, Lam J, et al. : Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145.
9. Holdright D, Patel D, Cunningham D, et al. : Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994, 24:39-45.
10. Cairns JA, Gent M, Singer J, et al. : Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985, 313:1369-1375.
11. Lewis H Jr, Davis JW, Archibald DG, et al. : Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983, 309:396 403.
12. Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996, 276:811-815.
13. Cairns JA, Theroux P, Lewis HD Jr, et al. : Antithrombotic agents in coronary artery disease. Chest 1998, 114 (suppl):611S-633S.
14. Leizororovicz A, Simonneau G, Decousis H, Boissel JP: Comparison of efficacy and safety of low-molecularweight heparins and unfractionated heparin in initial treatment of venous thrombosis: a meta-analysis. BMJ 1994, 309:299-304.
15. Lensing AWA, Prins MH, Davidson BL, Hirsch J: Treatment of deep-vein thrombosis with low molecular-weight heparins: a meta-analysis. Arch Intern Med 1995, 155:601-607.
16. The Columbus Investigators: Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Eng J Med 1997, 337:657 662.
17. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992, 79 1-17.
18. Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688 698.
19. Beguin S, Mardiguian J, Lindhout T, Hemker HC: The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989, 61:30-34.
20. Barrowcliffe TW, Merton RE, Havercroft SJ, et al. : Low-affinit heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984, 34:125-133.
21. Young E, Wells P, Holloway S, et al. : Ex-vivo and in-vitro evidence that low-molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994, 71:300-304.
22. Carter CJ, Kelton JG, Hirsch J, et al. : The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins in rabbits. Blood 1982, 59:1339 1345.
23. Bergqvist D, Burmark US, Frisell J, et al. : Prospective doubleblind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986, 16(suppl 2):11-18.
24. Levine M, Gent M, Hirsch J, et al. : A comparison of lowmolecular weight heparin administered primarily at home with unfractionated heparin in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677-681.
25. Koopman MM, Prandoni P, Piovella F, et al. : Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared to subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996, 334:682 687.
26. Cohen M, Demers C, Gurfinkel EP, et al. : A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447 452.
27. Gurfinkel EP, Manos EJ, Mejail RI, et al. : Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995, 26 313 318.
28. Fragmin during Instability in Coronary Artery Disease (FRISC) study group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561-568.
29. Klein W, Buchwald A, Hillis SE, et al. : Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96 61-68.
30. Antman EM, McCabe CH, Gurfinkel EP, et al. : Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infraction: Results of the Thrombolyis In Myocardial Infarction (TIMI) 11B Trial. Circulation 1999, 100:1593-1601.
31. The FRAX. I. S. Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX. I. S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999 20:1553-1562.
32. FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators: Long-term low-molecular weight heparin in unstable coronary-artery disease: FRISC II prospective randomized multicenter study. Lancet 1999, 354:701-707.
33. Goodma S, Langer A, Demers C, et al. : One year follow-up of the ESSENCE trial (enoxaparin vs. heparin in unstabl angina/non-Q-wave myocardial infarction): sustained clinical benefit [abstract]. Can J Cardiol 1998, 14 122F.
34. Raschke, RA, Reilly RM, Guidry JR, et al. : The weight based heparin nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993, 119:874-881.
35. Becker RC, Ball SP, Eisenberg P, et al. : A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Am Heart J 1999, 137:59-71.
36. Antman EM, Cohen M, Radley D, et al. : Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction. TIMI 11B-ESSENCE Meta-Analysis. Circulation 1999, 100 1602-1608.
37. Mark DB, Cowper PA, Berkowitz SD, et al. : Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients Results from the ESSENCE randomized trial. Circulation 1998, 97:1702-1707.
38. Balen RM, Marra CA, Zed PJ, et al. : Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999, in press.
39. Ernofsson M, Strekerud F, Toss H, et al. : Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998, 79:491-494.
40. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentration and comparisons with low-molecular weight heparin and with direct thrombin inhibitor. Circulation 1998, 97:251-256.
41. Hansen J-B, Sandset PM: Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for the difference in therapeutic efficacy. Thromb Res 1998, 91:177-181.
42. Montalescot G, Philippe F, Ankri A, et al. : Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation 1998, 98:294-299.
43. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infraction. N Engl J Med 1998, 338:1488-1497.
44. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acut coronary syndromes. N Engl J Med 1998, 339:436-443.